Shareholders Voted to Approve Both SAIF Partners Proposals at Special Meeting 
Newly Elected Directors Are Committed to Support and Execute the Announced Payout of Dividends and Unlock Sinovac’s Long-Term Value for All Shareholders Through the Resumption of Trading of Sinovac’s Common Shares 
NEW YORK -- (BUSINESS WIRE) -- 
SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), today announced that Sinovac Biotech Ltd. (“Sinovac” or the “Company”) shareholders voted to approve SAIF Partners’ proposals to remove the Company’s incumbent directors and to elect SAIF Partners’ slate of ten highly qualified director nominees to the Board of Directors (the “Board”) at Sinovac’s Special Meeting of Shareholders (the “Special Meeting”). 
On July 8, 2025, at 8:00 p.m. Atlantic Standard Time, Sinovac’s incumbent Chairman Chiang Li convened, then immediately purported to adjourn, the Special Meeting without allowing shareholders to participate. SAIF Partners representatives, alongside those of other shareholders, had arrived at the Special Meeting intending to participate in the meeting. 
Subsequently, the shareholder representatives present convened a continuation of the Special Meeting, chaired by incumbent Sinovac Director Mr. Yuk Lam Lo, the only remaining director on the incumbent Board approved by Privy Council. During the Special Meeting, Sinovac’s shareholders voted to approve both of SAIF Partners’ proposals, based on a tabulation of votes cast on SAIF Partners’ gold proxy card and the Company’s white proxy card. 
The newly elected directors of the Company are committed to supporting and executing Sinovac’s announced payout of dividends and working closely with Sinovac’s management to unlock long-term value for all shareholders by pursuing the resumption of trading of the Company’s common shares to help Sinovac realize its tremendous potential. 
About SAIF Partners 
SAIF Partners is a leading Asian private equity firm with cumulative assets under management of over $4 billion. SAIF Partners is an active lead investor working closely with its portfolio companies to develop their business both organically and through acquisitions, seeking synergistic cooperation among them, as well as enhancing shareholder value via promotion of good corporate governance and best management practices. 
 
 

Tags：